Triple-Negative Breast Cancer Therapy Prediction via Molecular Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods for triple-negative breast tumors lack sensitivity and specificity, unable to monitor patients effectively or guide individualized treatment decisions due to limitations in detecting and profiling signal transduction pathways, particularly in metastatic stages where tumors evolve rapidly.
Innovation Solution
A method involving the analysis of tumor cells from triple-negative breast tumors to determine the expression levels of VEGFR2, c-KIT, HER1, and IGF-1R, using proximity dual detection assays like CEER, to predict the response to a combination of bevacizumab, carboplatin, and paclitaxel therapy, enabling personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cancer treatment methods are used for triple-negative breast tumors, then treatment can be administered, but sensitivity and specificity in detecting signal transduction pathways are insufficient
Solution Approach 1:
The patent changes the detection parameters by measuring specific signal transduction pathway components (EGFR, VEGFR2, HER2, PDGFRβ, c-KIT, IGF-1R) and their phosphorylation states instead of using general treatment methods. This allows precise quantification of pathway activation levels to predict treatment response
Solution Approach 2:
The patent replaces conventional treatment decision-making with a molecular profiling system that uses antibody-based detection assays to measure signal transduction pathway activity, substituting clinical judgment with objective molecular data for treatment selection
2Measurement precision
If signal transduction pathway profiling is performed to guide treatment, then treatment response prediction improves, but device complexity and assay requirements increase
Solution Approach 1:
The patent uses a universal antibody-based detection platform that can measure multiple signal transduction pathway components (EGFR, VEGFR2, HER2, PDGFRβ, c-KIT, IGF-1R) and their phosphorylation states through standardized assays, allowing one system to perform multiple detection functions
Solution Approach 2:
The patent segments the complex signal transduction analysis into discrete measurable components (receptor expression levels, phosphorylation states of specific residues) that can be assessed independently through separate antibody assays, making the overall complex system manageable
3Productivity
If conventional treatment monitoring is used, then treatment can be administered, but real-time monitoring capability is lacking
Solution Approach 1:
The patent performs preliminary molecular profiling of signal transduction pathways before treatment initiation and at subsequent time points, establishing a baseline and enabling proactive treatment adjustment based on predicted response rather than waiting for clinical outcomes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.